Chimaerin beta 3 Antibody


Chimaerin beta 3 Antibody

Product no.: CHIM-212AP
$295.00
$265.00


General Information

 

 

Product

 

Chimaerin beta 3 Antibody

Description

Affinity Purified Beta-Chimaerin isoform 3 Antibody

Verified Applications

ELISA, IP, WB

Host

Rabbit

Species Cross Reactivity

Human, Mouse, Rat

Immunogen

Synthetic peptide taken within amino acid region 1-100 on human beta-chimaerin isoform 3 protein.

Accession #

NCBINP_001279998.1


Physical Properties

 

 

Quantity

 

100 µg

Volume

200 µl

Concentration

0.68-0.71 µg/µl in antibody stabilization buffer

Form

Affinity Purified

Clonality

Polyclonal

Storage

-20C for long term storage


Application Protocol

DB

1:10,000

ELISA

1:10,000

Immunoprecipitation 1:200

Western Blot

1:500


Protein

 

Uniprot #

 

P52757

Overview

GTPase-activating protein for p21-rac.  May play role in progression from low-grade to high-grade tumors.

Molecular Function

Metal binding; Zinc

Subcellular Location

Membrane

Expression

Brain, pancreas, heart, placenta.  Weakly expressed in kidney and liver.

Structure

Contains 1 phorbol-ester/DAG-type zinc finger; 1 Rho-GAP domain; 1 SH2 domain.

Alternative Nomenclature

ARHGAP3 antibody

BCH antibody

Beta chimerin antibody

Chimaerin3 antibody

CHN3 antibody

MGC138360 antibody

Rho GTPase activating protein 3 antibody

RHOGAP3 antibody

   

Protein information supplied by UniProt
 

 

Accessories

Product Note Status Price
Chimaerin beta 3 Antibody FITC Chimaerin beta 3 Antibody FITC
CHIMB3-FITC $350.00 *
Chimaerin beta 3 Antibody BIOTIN Chimaerin beta 3 Antibody BIOTIN
CHIMB3-BIOTIN $350.00 *
Chimaerin beta 3 Blocking Peptide Chimaerin beta 3 Blocking Peptide
P-CHIMB3 $145.00 *
Chimaerin beta 3 Positive Control Chimaerin beta 3 Positive Control
PC-CHIMB3 $185.00 *
Display accessory details

We also recommend

PCHIM-140AP
CHIM-101AP
CHIM-201AP

Browse these categories as well: G-Protein Coupled Receptors, Guanylate Cyclases & GTPases, Primaries, Neurotransmission, Neuroscience, Regulation, Cancer Research, Protease inhibitor Targets